Brief: Erytech Updates On Results Of Trybeca-1 Phase 3 Trial Of Eryaspase

Phaxiam Therapeutics SA

25/10/2021 06:08

Oct 25 (Reuters) - Erytech Pharma SA  ERYP.PA :
    * REG-ERYTECH ANNOUNCES RESULTS FROM TRYBECA-1 PHASE 3 TRIAL OF ERYASPASE IN
PATIENTS WITH SECOND-LINE ADVANCED PANCREATIC CANCER
    * TRIAL DID NOT MEET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL
    * WILL REVIEW STRATEGIC AND PARTNERING ALTERNATIVES, INCLUDING FOR
THEFURTHER
DEVELOPMENT AND COMMERCIALIZATION OF ERYASPASE
    * SAFETY PROFILE OF ERYASPASE WAS CONSISTENT WITH EARLIER CLINICAL TRIALS
RESULTS
AND SAFETY REVIEWS
    * WILL NOW FOCUS ON ITS LATE-STAGE PROGRAM IN HYPERSENSITIVE ALL AND
CONFIRMS ITS
INTENTION TO SUBMIT A BLA BEFORE END OF YEAR
    * KEY SECONDARY ENDPOINTS OF TRIAL, INCLUDING PROGRESSION-FREE SURVIVAL,
DISEASE
CONTROL RATE AND OBJECTIVE RESPONSE RATE, SHOWED BENEFIT IN FAVOR OF ERYASPASE
    * ERYTECH PHARMA SA - FURTHER ANALYSIS OF DATA WILL BE PERFORMED, AND FULL
RESULTS
WILL BE PRESENTED AT AN UPCOMING MEDICAL CONFERENCE
    * WILL REVIEW STRATEGIC AND PARTNERING ALTERNATIVES, INCLUDING FOR FURTHER
DEVELOPMENT AND COMMERCIALIZATION OF ERYASPASE
    * WILL NOW FOCUS ON ITS LATE-STAGE PROGRAM IN ACUTE LYMPHOBLASTIC LEUKEMIA
(ALL)
AND PURSUE A PATH TO APPROVAL IN HYPERSENSITIVE ALL BASED ON POSITIVE RESULTS OF
NOPHO-SPONSORED PHASE 2 TRIAL
    * REITERATES ITS INTENTION TO SUBMIT A BLA BEFORE END OF YEAR
    * WILL EVALUATE OUR STRATEGIC AND PARTNERING OPTIONS IN COMING WEEKS AND
WILL
PROVIDE UPDATED GUIDANCE ON OUR GLOBAL CORPORATE STRATEGY LATER IN YEAR

Source text for Eikon:  ID:nGNEbMhfs3 
Further company coverage:  ERYP.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))